Cabergoline Tablets 0.25 mg / 0.5 mg Manufacturer & Exporter India

Product Overview
Key Features
Therapeutic Uses
Dosage Form Advantages

Cabergoline Tablets are a long-acting dopamine receptor agonist formulation primarily indicated for the effective management of hyperprolactinemia and prolactin-related endocrine disorders. By directly stimulating dopamine D2 receptors, Cabergoline inhibits prolactin secretion from the pituitary gland, helping restore hormonal balance and reproductive health.

Genliva Wellness LLP, a leading pharmaceutical contract manufacturing company in India, offers premium-quality Cabergoline Tablets developed through GMP & ISO-certified manufacturing facilities. The product is formulated with high-grade active pharmaceutical ingredients (API) to ensure superior efficacy, safety, and long-term stability.

As a trusted third-party pharma manufacturer and global exporter, Genliva provides flexible solutions including custom formulations, private labeling, bulk manufacturing, and export-oriented packaging, making it an ideal partner for distributors, importers, and healthcare companies worldwide.

Manufactured in WHO-GMP compliant and ISO-certified pharmaceutical units
High potency Cabergoline formulation with excellent bioavailability
Supports long-acting therapeutic effect with reduced dosing frequency
Strict adherence to international quality standards and regulatory guidelines
Available in multiple strengths such as 0.25 mg and 0.5 mg tablets
Suitable for bulk production, third-party manufacturing, and contract manufacturing services
Backed by Genliva’s expertise in global pharmaceutical supply chain management

Cabergoline Tablets are widely prescribed in endocrinology and gynecology for:

Treatment of hyperprolactinemia (elevated prolactin levels)
Management of prolactin-secreting pituitary adenomas (prolactinomas)
Regulation of menstrual disorders such as amenorrhea and oligomenorrhea
Treatment of female infertility due to hormonal imbalance
Management of galactorrhea (abnormal milk secretion)
Adjunct therapy in Parkinson’s disease (dopamine deficiency conditions)
Restoration of normal ovulation and reproductive hormone balance
Prevention of complications related to chronic endocrine dysfunction

Oral tablet dosage ensures ease of administration and improved patient adherence
Long half-life allows less frequent dosing compared to other dopamine agonists
Provides consistent plasma drug concentration for sustained therapeutic action
Compact and stable dosage form suitable for large-scale distribution and export logistics
Cost-effective formulation ideal for emerging and regulated markets
Flexible packaging formats including blister packs, alu-alu, and bulk containers